LBF20406OX02: Difference between revisions
No edit summary |
No edit summary |
||
(6 intermediate revisions by 2 users not shown) | |||
Line 6: | Line 6: | ||
|LipidBank=DFA8157 | |LipidBank=DFA8157 | ||
|LipidMaps=LMFA03060019 | |LipidMaps=LMFA03060019 | ||
|SysName=12- | |SysName=12-Oxo- (cis-5,cis-8,trans-10,cis-14) -eicosatetraenoic acid | ||
|Common Name=&&12- | |Common Name=&&12-Oxo- (5Z,8Z,10E,14Z) -eicosatetraenoic acid&& | ||
|UV Spectra= | |UV Spectra= lambda max: 280nm epsilon : 30,000 | ||
|Source=12-OxoETE is synthesized by human platelets and Aplaysia nervous tissue after incubation with arachidonic acid [[Reference:Falgueyret_JP:Leblanc_Y:Riendeau_D:,FEBS Lett.,1990,262,197|{{RelationTable/GetFirstAuthor|Reference:Falgueyret_JP:Leblanc_Y:Riendeau_D:,FEBS Lett.,1990,262,197}}]][[Reference:Fruteau_de_Laclos_B:Maclouf_J:Poubelle_P:Borgeat_P:,Prostaglandins,1987,33,315|{{RelationTable/GetFirstAuthor|Reference:Fruteau_de_Laclos_B:Maclouf_J:Poubelle_P:Borgeat_P:,Prostaglandins,1987,33,315}}]]. Microsomal fractions of various tissues will reduce 12-oxoETE to 12(S)-HETE or a mixture of 12(S)- and 12(R)-HETE [[Reference:Falgueyret_JP:Leblanc_Y:Riendeau_D:,FEBS Lett.,1990,262,197|{{RelationTable/GetFirstAuthor|Reference:Falgueyret_JP:Leblanc_Y:Riendeau_D:,FEBS Lett.,1990,262,197}}]][[Reference:Falgueyret_JP:Leblanc_Y:Rokach_J:Riendeau_D:,Biochem. Biophys. Res. Commun.,1988,156,1083|{{RelationTable/GetFirstAuthor|Reference:Falgueyret_JP:Leblanc_Y:Rokach_J:Riendeau_D:,Biochem. Biophys. Res. Commun.,1988,156,1083}}]]. | |Source=12-OxoETE is synthesized by human platelets and Aplaysia nervous tissue after incubation with arachidonic acid [[Reference:Falgueyret_JP:Leblanc_Y:Riendeau_D:,FEBS Lett.,1990,262,197|{{RelationTable/GetFirstAuthor|Reference:Falgueyret_JP:Leblanc_Y:Riendeau_D:,FEBS Lett.,1990,262,197}}]][[Reference:Fruteau_de_Laclos_B:Maclouf_J:Poubelle_P:Borgeat_P:,Prostaglandins,1987,33,315|{{RelationTable/GetFirstAuthor|Reference:Fruteau_de_Laclos_B:Maclouf_J:Poubelle_P:Borgeat_P:,Prostaglandins,1987,33,315}}]]. Microsomal fractions of various tissues will reduce 12-oxoETE to 12(S)-HETE or a mixture of 12(S)- and 12(R)-HETE [[Reference:Falgueyret_JP:Leblanc_Y:Riendeau_D:,FEBS Lett.,1990,262,197|{{RelationTable/GetFirstAuthor|Reference:Falgueyret_JP:Leblanc_Y:Riendeau_D:,FEBS Lett.,1990,262,197}}]][[Reference:Falgueyret_JP:Leblanc_Y:Rokach_J:Riendeau_D:,Biochem. Biophys. Res. Commun.,1988,156,1083|{{RelationTable/GetFirstAuthor|Reference:Falgueyret_JP:Leblanc_Y:Rokach_J:Riendeau_D:,Biochem. Biophys. Res. Commun.,1988,156,1083}}]]. | ||
|Chemical Synthesis= | |Chemical Synthesis= |
Latest revision as of 07:31, 21 October 2010
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | DFA8157 |
LipidMaps | LMFA03060019 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20406OX02 |
12-Oxo- (5Z,8Z,10E,14Z) -eicosatetraenoic acid | |
---|---|
Structural Information | |
12-Oxo- (cis-5,cis-8,trans-10,cis-14) -eicosatetraenoic acid | |
| |
12-OxoETE/12-KETE | |
Formula | C20H30O3 |
Exact Mass | 318.21949482599996 |
Average Mass | 318.4504 |
SMILES | C(CC=CCC(C=CC=CCC=CCCCC(O)=O)=O)CCC |
Physicochemical Information | |
12-OxoETE is synthesized by human platelets and Aplaysia nervous tissue after incubation with arachidonic acid Falgueyret_JP et al. Fruteau_de_Laclos_B et al.. Microsomal fractions of various tissues will reduce 12-oxoETE to 12(S)-HETE or a mixture of 12(S)- and 12(R)-HETE Falgueyret_JP et al. Falgueyret_JP et al.. | |
12-OxoETE induces a rapid, dose related increase of cytoplasmic free calcium via a leukotriene B4 receptor or a common activation sequence Naccache_PH et al.. | |
Spectral Information | |
Mass Spectra | |
UV Spectra | λ max: 280nm ε : 30,000 |
IR Spectra | |
NMR Spectra | |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|